OKYO Pharma Limited - Patent for treating Ocular Pain and Inflammation
OKYO Pharma has
The work recited in this patent lays out the potential of this class of lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects and potential abuse associated with opioid medications. The Company originally announced in
"The publication of this patent on our BAM-lipidated analogues provides key IP protection crucial for bringing forward a candidate from this class into the clinic," said Dr.
About OKYO Pharma
OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
OKYO Pharma Limited
| || |
+44 (0)20 7495 2379
Optiva Securities Limited
| || |
+44 (0)20 3981 4173
For further information, please visit the Company's website at www.okyopharma.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS
Quick facts: Okyo Pharma Limited
Market Cap: -
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE